KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aquestive Therapeutics (AQST) EBT (2017 - 2025)

Aquestive Therapeutics (AQST) has 8 years of EBT data on record, last reported at -$31.9 million in Q4 2025.

  • For Q4 2025, EBT fell 86.65% year-over-year to -$31.9 million; the TTM value through Dec 2025 reached -$83.8 million, down 89.77%, while the annual FY2025 figure was -$83.8 million, 89.77% down from the prior year.
  • EBT reached -$31.9 million in Q4 2025 per AQST's latest filing, down from -$15.4 million in the prior quarter.
  • Across five years, EBT topped out at $8.1 million in Q1 2023 and bottomed at -$31.9 million in Q4 2025.
  • Average EBT over 5 years is -$13.0 million, with a median of -$13.0 million recorded in 2022.
  • Peak YoY movement for EBT: crashed 429.86% in 2021, then surged 161.03% in 2023.
  • A 5-year view of EBT shows it stood at -$28.9 million in 2021, then skyrocketed by 57.33% to -$12.4 million in 2022, then surged by 35.15% to -$8.0 million in 2023, then tumbled by 113.1% to -$17.1 million in 2024, then tumbled by 86.65% to -$31.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBT were -$31.9 million in Q4 2025, -$15.4 million in Q3 2025, and -$13.5 million in Q2 2025.